Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
September 30, 2026 -8.641M
June 30, 2026 -8.034M
March 31, 2026 -9.082M
December 31, 2025 -7.900M
September 30, 2025 -6.617M
June 30, 2025 -7.858M
March 31, 2025 -7.149M
December 31, 2024 -6.025M
September 30, 2024 -4.488M
June 30, 2024 -4.440M
March 31, 2024 -6.653M
December 31, 2023 -3.580M
September 30, 2023 -4.824M
June 30, 2023 -5.066M
March 31, 2023 -5.089M
December 31, 2022 -2.448M
September 30, 2022 -2.232M
June 30, 2022 -2.470M
March 31, 2022 -3.888M
December 31, 2021 -2.779M
September 30, 2021 -2.904M
June 30, 2021 -2.188M
March 31, 2021 -4.313M
December 31, 2020 -3.202M
September 30, 2020 -2.486M
Date Value
June 30, 2020 -0.7883M
March 31, 2020 -2.978M
December 31, 2019 -1.858M
September 30, 2019 -1.306M
June 30, 2019 -2.852M
March 31, 2019 -3.134M
December 31, 2018
September 30, 2018 -1.799M
June 30, 2018 -1.003M
March 31, 2018 -0.935M
December 31, 2017 -0.9881M
September 30, 2017 -0.8278M
June 30, 2017 -1.405M
March 31, 2017 -0.8232M
December 31, 2016
September 30, 2016 -0.9353M
June 30, 2016 -0.4272M
March 31, 2016 -0.3959M
December 31, 2015 -0.3726M
September 30, 2015 -0.1165M
June 30, 2015 -0.5838M
March 31, 2015 -0.3465M
December 31, 2014 -0.1147M
September 30, 2014 -0.7268M
June 30, 2014 -1.855M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. -192.40M
Nektar Therapeutics -71.93M
Fortress Biotech, Inc. -6.197M
ACADIA Pharmaceuticals, Inc. 11.50M
Alnylam Pharmaceuticals, Inc. 340.98M